Background Numerous retrospective studies have shown associations between the number of intratumoral immune cells and patient outcomes for individual cancers treated with specific therapies. However, the clinical value of using a digital pathology platform to enumerate intratumoral immune biomarkers prospectively in the pan cancer setting has not been established. Methods We developed ImmunoProfile, a clinical workflow combining automated multiplex immunofluorescence tissue staining, digital slide imaging, and machine learning-assisted scoring to quantify intratumoral CD8+, PD1+, CD8+PD1+, and FOXP3+ immune cells and PDL1 expression in formalin-fixed, paraffin-embedded tissue samples in a standardized and reproducible manner. Over three years, we prospectively applied ImmunoProfile to biopsies collected from 2,023 unselected cancer patients in the clinical laboratory. We correlated the results with patient survival. Results In the pan cancer cohort, patients with intratumoral CD8+ or PD1+ cells in the top or middle tertiles had significantly lower risks of death than those in the bottom (CD8+: (high vs. low) HR 0.62 [95% CI 0.48 to 0.81], (middle vs. low) HR 0.82 [95% CI 0.67 to 0.99], Wald p=0.002]; PD1+: (high vs. low) HR 0.65 [95% CI 0.51 to 0.83], (middle vs. low) HR 0.74 [95% CI: 0.60 to 0.90], p=0.0009) after controlling for risk factors, including cancer type. In subset analyses, patients with high intratumoral CD8+, PD1+, and/or CD8+PD1+ cells had lower risks of death from non-small cell lung, colorectal, breast, esophagogastric, head and neck, pancreatic, and ovarian cancers after controlling for clinical risk factors, including stage, and despite distinct therapies. Conclusions Enumerating intratumoral CD8+ and PD1+ cells with a clinically validated digital pathology platform predicts patient survival across cancer types independent of clinical stage and despite disparate therapies.

The authors have declared no competing interest.

This study was funded by the Dana-Farber Cancer Institute and its charitable contributors.

I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.

Yes

The details of the IRB/oversight body that provided approval or exemption for the research described are given below:

The IRB of the Dana-Farber Cancer Institute gave ethical approval for this work.

I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.

Yes

I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).

Yes

I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.

Yes

All data produced in the present work are contained in the manuscript.